Mechanical Venous Thrombectomy Systems Market By Product (Aspiration Thrombectomy Systems, Mechanical Retrieval and Coring Systems, Rheolytic and Pharmacomechanical Thrombectomy Systems, Rotational Thrombectomy Systems, Hybrid Thrombectomy Systems); By Application (Pulmonary Embolism, Deep-Vein Thrombosis); By End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Mechanical Venous Thrombectomy Systems Market : Procedure Adoption Converts Venous Thromboembolism Burden into Device Revenue

The Global Mechanical Venous Thrombectomy Systems Market was valued at USD 1.05 billion in 2025 and is projected to reach USD 2.66 billion by 2032, expanding at a CAGR of 14.2% during 2026–2032, according to Strategic Market Research.

 

Mechanical venous thrombectomy systems remove clots from the deep venous system using aspiration, rheolytic saline jets, and mechanical maceration or coring. By reducing reliance on thrombolytic drugs, these devices support faster clot removal, lower bleeding risk, and improved blood-flow restoration in selected deep vein thrombosis and pulmonary embolism cases.

 

A Large Disease Pool Narrows into a Selective Procedure Market

Up to 900,000 people are affected by venous thromboembolism annually in the United States, while the CDC estimates that 60,000 to 100,000 deaths are associated with the condition each year. This disease burden supports a substantial hospital screening population, but only a limited share of patients proceeds to mechanical intervention. Most patients are treated with anticoagulation, while lower-risk pulmonary embolism and many uncomplicated DVT cases do not require catheter-based clot removal.

The strongest public procedure evidence comes from an analysis of 313,522 Medicare fee-for-service beneficiaries hospitalized with pulmonary embolism between June 2018 and September 2023. Of these patients, 28,597 received a catheter-based intervention and 14,918 underwent mechanical thrombectomy. Mechanical thrombectomy accounted for approximately 4.76% of the total hospitalized cohort and 52.2% of patients receiving a catheter-based intervention.

Catheter-based intervention penetration increased from 5.92% to 14.1% during the study period, with mechanical thrombectomy responsible for much of the increase. The expansion indicates that hospitals are moving beyond anticoagulation and catheter-directed thrombolysis for selected higher-risk patients, particularly where interventional teams and pulmonary embolism response programs are available.

Procedure use remains concentrated in large and teaching hospitals. Smaller institutions recorded substantially lower intervention rates, reflecting limited catheter-laboratory capacity, fewer specialist teams, weaker transfer pathways, and lower procedural volumes. This concentration makes high-volume referral centers, academic medical systems, and hospitals with established pulmonary embolism response teams the most commercially important accounts for device manufacturers.

 

Guidelines Create a Clearer Path for Selected Pulmonary Embolism Patients

The 2026 AHA/ACC pulmonary embolism guideline introduced a more detailed clinical-category framework for identifying patients who may require advanced intervention. Mechanical thrombectomy is considered reasonable for patients in the most severe E1 category and may be considered for selected patients classified as D1 or D2. The guideline also recommends pulmonary embolism response teams to improve the timeliness of care.

The guidance supports structured treatment pathways for patients with cardiopulmonary failure, deterioration, substantial right-heart strain, or other elevated-risk markers. Hospitals can use these categories to develop referral protocols and activate multidisciplinary teams.

Anticoagulation remains the primary treatment for most eligible patients, so expansion depends on identifying groups in which mechanical clot removal offers a meaningful clinical or operational advantage.

 

Randomized Evidence Strengthens the Case for Hospital Adoption

The PEERLESS randomized trial enrolled 550 patients with intermediate-risk pulmonary embolism who had already been selected for catheter-based intervention. The trial compared large-bore mechanical thrombectomy with catheter-directed thrombolysis.

Mechanical thrombectomy was associated with less clinical deterioration, fewer requirements for bailout treatment, and lower post-procedure intensive-care utilization. Major bleeding outcomes were broadly comparable, while the trial did not demonstrate a mortality difference between the two treatment groups.

PEERLESS supports mechanical thrombectomy as an alternative after a hospital has selected catheter intervention. Hospitals increasingly evaluate platforms on ICU requirements, treatment escalation, bleeding risk, procedure duration, staffing, and resource utilization rather than clot removal alone.

STORM-PE extended the evidence base by comparing mechanical thrombectomy plus anticoagulation with anticoagulation alone in intermediate-risk pulmonary embolism. The study reported greater improvement in the right-ventricular-to-left-ventricular ratio and faster normalization of vital signs in the thrombectomy group, with similar overall rates of major bleeding and adverse events.

Because anticoagulation alone treats a much larger patient population, further evidence on mortality, deterioration, hospital stay, readmission, recovery, and episode cost could materially influence coverage and hospital protocols.

 

Pulmonary Embolism Remains the Primary Procedure-Growth Segment

Pulmonary embolism represented an estimated 58.0% share of the global market in 2025, equivalent to approximately USD 609 million in revenue. Strategic Market Research projects this segment to expand at a CAGR of 15.3% during 2026–2032 and reach nearly USD 1.65 billion by 2032, supported by rising intervention penetration, guideline recognition, and expanding randomized evidence.

Most pulmonary embolism thrombectomy procedures are performed in inpatient hospitals. These institutions must coordinate emergency medicine, pulmonary and critical care, interventional cardiology, interventional radiology, vascular medicine, anesthesia, intensive care, and hospital procurement.

Recurring device demand depends on thrombectomy being included in institutional treatment protocols. A system may receive regulatory clearance and be stocked by a hospital, but durable revenue is generated only when physicians consistently identify eligible patients and route them to the procedure.

Hospital buyers also examine the effect of a system on post-procedure monitoring, ICU use, blood loss, treatment escalation, thrombolytic exposure, catheter-laboratory time, and length of stay. Suppliers that support a clear hospital-resource argument are better positioned to defend procedure costs under bundled inpatient payments.

 

Deep-Vein Thrombosis Creates a Broader but More Variable Opportunity

Deep-vein thrombosis accounted for an estimated 42.0% market share and approximately USD 441 million in revenue in 2025. The segment is projected to reach about USD 1.01 billion by 2032, expanding at a CAGR of 12.6% during 2026–2032 as hospitals and selected outpatient centers adopt thrombectomy for proximal, iliofemoral, chronic, wall-adherent, or extensive venous thrombus.

The DVT segment has a more variable treatment pathway. Many patients respond to anticoagulation, while others receive catheter-directed thrombolysis, pharmacomechanical thrombectomy, venoplasty, stenting, or conservative treatment. Symptom duration, thrombus age, anatomy, venous compression, bleeding risk, underlying obstruction, and the likelihood of functional improvement affect procedure selection.

Commercial-payer policies also vary. Some insurers continue to classify mechanical thrombectomy for acute iliofemoral DVT as investigational or unproven. This can lead to prior-authorization requirements, denials, slower outpatient adoption, and differences in access among health plans.

Growth in the DVT segment will depend on evidence showing durable symptom improvement, reduction in post-thrombotic complications, predictable reimbursement, and favorable economics for outpatient facilities.

 

Reimbursement Supports Procedure Growth but Intensifies Cost Scrutiny

U.S. procedure coding provides a defined reimbursement pathway for venous mechanical thrombectomy. CPT 37187 covers initial venous mechanical thrombectomy, while CPT 37188 addresses repeat thrombectomy on a subsequent treatment day under defined circumstances.

Illustrative 2026 national payments for CPT 37187 were approximately USD 11,340.57 in the hospital outpatient setting and USD 7,800.37 in ambulatory surgery centers. These payment pathways support selected outpatient DVT procedures and indicate that mechanical thrombectomy has an established procedural reimbursement structure.

Inpatient pulmonary embolism procedures are generally paid through bundled hospital payment systems. Hospitals must absorb the acquisition cost of the thrombectomy system, procedural disposables, imaging, staffing, anesthesia, monitoring, and post-procedure care within the total episode economics.

Inpatient hospitals represented an estimated 82.0% of 2025 market revenue, or approximately USD 861 million. This segment is projected to grow at a CAGR of 13.7% and reach about USD 2.12 billion by 2032. Hospital outpatient departments and ambulatory surgery centers held the remaining 18.0%, equivalent to approximately USD 189 million, but are expected to expand faster at a CAGR of 16.4% and generate nearly USD 547 million by 2032 as selected DVT procedures migrate to lower-cost settings.

This structure places pressure on suppliers to demonstrate measurable value. Hospitals may prefer platforms that reduce thrombolytic use, treatment escalation, ICU utilization, repeated procedures, or operational complexity. Procurement teams also examine the number of disposable components required per case and whether the supplier offers predictable procedure-based pricing.

Single-use catheters, tubing, collection devices, retrieval components, and procedure kits generated an estimated 78.0% share, or approximately USD 819 million, in 2025. This disposable segment is forecast to grow at a CAGR of 14.8% and reach about USD 2.15 billion by 2032. Aspiration pumps and other reusable or capital-support components accounted for approximately 22.0%, or USD 231 million, and are projected to reach nearly USD 507 million at an 11.9% CAGR.

 

Aspiration and Mechanical Retrieval Systems Shape Competition

The market includes aspiration thrombectomy systems, mechanical coring and retrieval devices, rheolytic or pharmacomechanical platforms, rotational systems, and hybrid technologies.

Aspiration thrombectomy systems held an estimated 47.0% market share in 2025, representing approximately USD 494 million. The segment is projected to reach about USD 1.33 billion by 2032 at a CAGR of 15.2%, supported by pulmonary embolism procedures and pump-based disposable pull-through.

Mechanical retrieval and coring systems accounted for an estimated 35.0% share and approximately USD 368 million in 2025. This segment is forecast to expand at a CAGR of 14.1% to around USD 925 million by 2032. Rheolytic, pharmacomechanical, rotational, and hybrid systems collectively represented the remaining 18.0%, or about USD 189 million, and are projected to reach nearly USD 405 million at an 11.5% CAGR.

Stryker’s FlowTriever and ClotTriever platforms, acquired through Inari Medical, are among the most visible dedicated systems. FlowTriever combines aspiration and mechanical clot engagement for pulmonary embolism, while ClotTriever removes thrombus from major peripheral veins. Their single-use structure links supplier revenue directly to procedure volume.

Penumbra’s Indigo platform uses pump-powered aspiration for pulmonary and peripheral vascular applications. Penumbra reported that its global thrombectomy revenue increased from approximately USD 815.5 million in 2024 to USD 947.9 million in 2025, representing 16.2% year-on-year growth. The figures include neurovascular, arterial, pulmonary, and peripheral products, but the company attributed U.S. thrombectomy growth mainly to higher sales volume and market penetration rather than price increases.

AngioDynamics competes through the AlphaVac aspiration system, while Boston Scientific participates through pharmacomechanical and peripheral-intervention technologies. Hospitals compare these devices according to vessel coverage, blood loss, catheter size, ability to remove organized clot, treatment time, requirement for thrombolytics, equipment requirements, training burden, safety record, clinical evidence, and total procedure cost.

 

Strategic Acquisitions Increase Portfolio and Contracting Pressure

Stryker completed its acquisition of Inari Medical in February 2025 for an aggregate purchase price of approximately USD 4.81 billion net of cash acquired. Before the acquisition, Inari’s VTE revenue reached USD 420.2 million during the first nine months of 2024, compared with USD 349.6 million during the same period in 2023, representing growth of 20.2%.

Boston Scientific announced an agreement in January 2026 to acquire Penumbra at an enterprise value of approximately USD 14.5 billion. The proposed transaction would add aspiration thrombectomy, stroke, embolization, pulmonary embolism, and peripheral vascular technologies to Boston Scientific’s cardiovascular portfolio.

These acquisitions reflect the strategic value of thrombectomy technologies, recurring disposables, specialist relationships, and access to high-volume hospitals. Larger owners can combine thrombectomy systems with broader cardiovascular portfolios, negotiate health-system contracts, fund randomized trials, support physician education, and expand distribution across international markets.

Independent manufacturers face increasing pressure to demonstrate distinctive clinical outcomes, procedure economics, or specialized anatomical capabilities. Smaller developers may increasingly rely on distribution partnerships, licensing agreements, strategic investment, or acquisition to reach hospitals at scale.

 

North America Leads While Asia-Pacific Records the Fastest Expansion

North America held an estimated 49.0% share of the global market in 2025, equivalent to approximately USD 515 million. The region is projected to expand at a CAGR of 13.8% and reach about USD 1.27 billion by 2032, supported by procedure claims, FDA clearances, reimbursement codes, randomized evidence, specialist hospital networks, and strong manufacturer activity.

Europe accounted for an estimated 27.0% share and approximately USD 284 million in 2025. The regional market is forecast to reach nearly USD 671 million by 2032 at a CAGR of 13.1%. Adoption remains more controlled in several public-health systems, with NICE continuing to apply special-governance or research conditions according to patient risk and treatment alternatives.

Asia-Pacific represented an estimated 18.0% share, or approximately USD 189 million, in 2025 and is projected to grow at the fastest regional CAGR of 16.7%, reaching about USD 557 million by 2032. Growth is expected to remain concentrated in major tertiary hospitals with interventional cardiology, vascular surgery, interventional radiology, intensive-care capability, and reimbursement support.

Latin America and the Middle East and Africa collectively accounted for the remaining estimated 6.0% share, or approximately USD 63 million, in 2025. These regions are projected to reach nearly USD 159 million by 2032 at a combined CAGR of 14.1%, with adoption centered on private and specialist hospitals.

 

Market Outlook

The Mechanical Venous Thrombectomy Systems Market is advancing through rising procedure penetration, clearer guideline positioning, expanding randomized evidence, dedicated hospital treatment teams, and strategic investment by large medical-device companies.

Pulmonary embolism will remain the primary revenue segment, aspiration systems will retain the largest system-type share, and single-use disposables will continue to generate most recurring revenue. Inpatient hospitals will remain dominant, although hospital outpatient departments and ambulatory surgery centers are expected to record faster growth as suitable DVT procedures shift to lower-cost settings.

 

Mechanical Venous Thrombectomy Systems Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.05 Billion
Revenue Forecast in 2032	USD 2.66 Billion
Overall Growth Rate	CAGR of 14.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Aspiration Thrombectomy Systems, Mechanical Retrieval and Coring Systems, Rheolytic and Pharmacomechanical Thrombectomy Systems, Rotational Thrombectomy Systems, Hybrid Thrombectomy Systems
By Application	Pulmonary Embolism, Deep-Vein Thrombosis
By End User	Hospitals, Ambulatory Surgery Centers, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising adoption of minimally invasive thrombectomy procedures for venous thromboembolic disorders • Increasing prevalence of pulmonary embolism and deep-vein thrombosis worldwide • Advancements in catheter-based thrombectomy technologies and growing preference for faster clot removal approaches
Customization Option	Available upon request